Actinogen Medical Limited (ASX:ACW) Managing Director and CEO, Dr Bill Ketelbey presents an update on the company's lead Alzheimer Phase II drug candidate XanADu and its expanded clinical development program for Xanamem.
- Xanamem lead compound for the treatment of Alzheimer's disease
- Also considered for other cortisol-associated cognitive impairment
- Reducing brain cortisol production
- Experienced board and management
- Expert clinical and scientific advisory boards
- Phase II trial currently underway
- Substantial institutional investment
- A huge market with significant unmet need
For more, watch the Managing Director and CEO, Dr Bill Ketelbey present.